Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide

Table 1 Baseline characteristics of the study population (n = 15)

	SFOH group, n = 9	Control group, n = 6	P value
Age (yr)	78 (35-90)	73 (49-91)	NS
Male/Female	9/0	4/2	NS
Cause of ESKD	4 DM, 2 GN, 2 UN, 1 ADPKD	2 DM, 2 HN, 1 GN, 1 UN	NS
Dialysis vintage (mo)	53 (19-131)	49 (21-67)	NS
Arteriovenous fistula/Graft	6/3	4/2	NS
Single pool Kt/V	1.56 ± 0.16	1.57 ± 0.29	NS
Dose of LanC pre switching (mg/d)	2250 (750-3000)	3000 (1500-3750)	NS
Number of LanC pills pre switching	3 (1-4)	4 (2-5)	NS
Calcium carbonate: n, dose (mg/d)	1, 750	1, 1250	NS
Cinacalcet: n, dose (mg/d)	1, 60	1, 30	NS
Paricalcitol: n, dose (mcg/wk)	6, 10 (7.5-15)	4, 5 (5-10)	NS

ADPKD: Adult dominant polycystic kidney disease; DM: Diabetes mellitus; ESKD: End stage kidney disease; GN: Glomerulonephritis; HN: Hypertensive nephrosclerosis; LanC: Lanthanum carbonate; NS: Non-significant; SFOH: Sucroferric oxyhydroxide.

Table 2 Paired comparisons, pre- and post-switching in the two groups

	SFOH group, n = 9			Control group, n = 6
	Baseline	6 wk	P value	Baseline	6 wk	P value
HCO3- (mmol/L)	22.41 ± 1.66	22.62 ± 2.25	0.889	21.05 ± 3.14	21.12 ± 2.27	0.917
pH	7.38 ± 0.03	7.39 ± 0.03	0.635	7.37 ± 0.033	7.36 ± 0.019	0.917
pCO2 (mmHg)	38.41 ± 3.29	38.37 ± 3.62	0.767	36.62 ± 4.55	37.82 ± 4.97	0.173
pO2 (mmHg)	93.1 ± 12.04	97.4 ± 10.08	0.953	82.8 ± 11.47	79.9 ± 14.35	0.463
BE (mmol/L)	-2.55 (-3.8 to -0.98)	-2.9 (-3.92 to -0.22)	0.722	-3.27 (-5.6 to -2.1)	-3.85 (-5.5 to -2)	0.917
K+ (mmol/L)	4.47 ± 0.32	4.38 ± 0.64	0.678	4.52 ± 0.23	4.6 ± 0.23	0.600
Phosphate (mmol/L)	1.57 ± 0.27	1.36 ± 0.38	0.214	1.34 ± 0.33	1.57 ± 0.48	0.249

The laboratory values refer to the average of the respective 2- and 3-d interdialytic interval and are expressed as mean ± SD or as median (min.-max.), P value denotes in group comparison (Wilcoxon signed rank test). SFOH: Sucroferric oxyhydroxide; BE: Base excess.